PMVP
PMV Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.29
+4.03%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 34.0K | — | 1.1M | 1.3M | 650.0K |
| Gross Profit | (34.0K) | — | (1.1M) | (1.3M) | (650.0K) |
| Operating Expenses | |||||
| R&D Expense | 64.0M | 69.9M | 57.4M | 54.6M | 51.7M |
| SG&A Expense | 15.6M | 16.3M | 26.9M | 24.2M | 24.7M |
| General & Admin Expense | 15.6M | 16.3M | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 79.6M | 86.2M | 84.3M | 78.9M | 76.4M |
| Cost and Expenses | 79.7M | 86.2M | 85.4M | 80.1M | 77.0M |
| Operating Income (EBIT) | (79.7M) | (86.2M) | (85.4M) | (80.1M) | (77.0M) |
| Non-Operating | |||||
| Interest Income | 4.5M | 6.3M | 10.7M | 11.2M | 3.6M |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 4.5M | 6.3M | 10.7M | 11.2M | 3.6M |
| Other Non-Op Income/Expense | 4.5M | 6.3M | 10.6M | 11.2M | 3.7M |
| Non-Operating Income (excl Interest) | (3.7M) | (6.3M) | (10.6M) | (11.2M) | (3.7M) |
| EBT (Pre-Tax Income) | (75.2M) | (79.9M) | (74.8M) | (69.0M) | (73.3M) |
| Income Tax Expense | 23.0K | (2.2M) | (16.1M) | 2.0K | (9.0K) |
| Bottom Line | |||||
| Net Income | (75.2M) | (77.7M) | (58.7M) | (69.0M) | (73.3M) |
| Earnings from Cont. Ops | (75.2M) | (77.7M) | (58.7M) | (69.0M) | (73.3M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (75.2M) | (77.7M) | (58.7M) | (69.0M) | (73.3M) |
| Per Share | |||||
| Basic EPS | ($1.42) | ($1.48) | ($1.14) | ($1.44) | ($1.61) |
| Diluted EPS | ($1.42) | ($1.48) | ($1.14) | ($1.44) | ($1.61) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 53.4M | 52.5M | 51.6M | 48.0M | 45.6M |
| Diluted Shares Outstanding | 53.4M | 52.5M | 51.6M | 48.0M | 45.6M |
| Profitability Metrics | |||||
| EBITDA | (75.9M) | (79.8M) | (73.7M) | (67.7M) | (72.7M) |
| D&A | 98.0K | 133.0K | 1.1M | 1.3M | 650.0K |
| EBIT | (76.0M) | (79.9M) | (74.8M) | (69.0M) | (73.3M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026